The global oncology and hematology landscape in 2026 is defined by a renewed focus on accessible, high-efficacy treatments for chronic blood disorders. In an era where precision medicine is often high-cost, the role of established therapeutic agents like hydroxycarbamide (also known as hydroxyurea) has remained a cornerstone of global healthcare. This versatile antineoplastic agent is a primary...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)